Evaluation of the efficacy and safety of various non-steroidal anti-inflammatory drugs in postmenopausal women with an inflammatory phenotype of osteoarthritis-Reference-Cited by-同舟云学术

Evaluation of the efficacy and safety of various non-steroidal anti-inflammatory drugs in postmenopausal women with an inflammatory phenotype of osteoarthritis

Published:2023-10-20 Issue:15 Volume: Page:104-110
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Shafieva I. A.¹^ORCID,Bulgakova S. V.²^ORCID,Shafieva A. V.³^ORCID,Kurmayev D. P.³^ORCID

Affiliation:

1. Clinics of Samara State Medical University

2. Samara State Medical University; Ministry of Health of Samara Region

3. Samara State Medical University

Abstract

Introduction. Non-steroidal anti-inflammatory drugs (NSAIDs) are currently the mainstay of the management for relieving pain syndrome in osteoarthritis (OA). NSAIDs are characterized by an individual reaction to medication, as well as a quite high frequency of gastrointestinal side effects. The issue of the disadvantages and advantages of a particular group of NSAIDs is still open.Aim. To evaluate the safety and efficacy of Meloxicam at a dose of 15 mg/day as compared with Nimesulide and placebo in postmenopausal women with an inflammatory phenotype of OA.Results and discussion. The frequency of all adverse events was comparable among the group of patients receiving meloxicam (40.0%), and lower than in the nimesulide group (48.0%), but higher than in the placebo group. A decrease in pain syndrome was observed as early as at 2 weeks of treatment in the group of patients receiving meloxicam. A significant decrease in WOMAC scores (overall result, pain syndrome, stiffness, function) was observed in the group of patients receiving meloxicam, and in the group of patients receiving nimesulide, after 3 weeks of treatment. meloxicam and nimesulide demonstrated high efficacy at 3 weeks compared with the initial VAS scores. The placebo group showed no efficacy.Conclusion. The frequency of all adverse events was lower while taking meloxicam as compared to nimesulide. Our results substantiate the concept to prescribe meloxicam at a dose 15 mg once daily for the treatment of pain and stiffness in post-menopausal women with OA.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference30 articles.

1. Magni A, Agostoni P, Bonezzi C, Massazza G, Menè P, Savarino V, Fornasari D. Management of Osteoarthritis: Expert Opinion on NSAIDs. Pain Ther. 2021;10(2):783–808. https://doi.org/10.1007/s40122-021-00260-1.

2. Ariani A, Manara M, Fioravanti A, Iannone F, Salaffi F, Ughi N. et al. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis. Reumatismo. 2019;71(Suppl. 1):5–21. https://doi.org/10.4081/reumatismo.2019.1188.

3. Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–350. https://doi.org/10.1016/j.semarthrit.2019.04.008.

4. Bruyère O, Cooper C, Pelletier JP, Maheu E, Rannou F, Branco J et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45(4 Suppl.):3–11. https://doi.org/10.1016/j.semarthrit.2015.11.010.

5. Cooper C, Chapurlat R, Al-Daghri N, Herrero-Beaumont G, Bruyère O, Rannou F et al. Safety of Oral Non-Selective Non-Steroidal AntiInflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019;36(Suppl. 1):15–24. https://doi.org/10.1007/s40266-019-00660-1.